(thirdQuint)Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation.

 Constipation is a common gastrointestinal problem estimated to effect 2-27 % of the population in United States .

 It is found more commonly in women and elderly .

 The prevelance of constipation and growing demand for treatment dictate the need for safe and effective treatment options .

 Lubiprostone is the first chloride channel activator approved by FDA for long term treatment of chronic idiopathic constipation in adult men and women .

 To provide a generic medicine to the U.

S population Dr Reddy's Laboratories intends to conduct this study to evaluate that the Lubiprostone manufactured by it is equally effective and safe as marketed AMITIZA(R) ( Lubiprostone) 24 mcg capsules (Sucampo Pharmaceuticals, Inc.

).

 Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation@highlight

The objective of this study is to evaluate the clinical equivalence and safety of the test formulation of Lubiprostone 24 mcg capsules manufactured by Dr Reddy's Laboratories Ltd compared to the marketed formulation AMITIZA(R) ( Lubiprostone) 24 mcg capsules (Sucampo Pharmaceuticals, Inc.

) in patients with confirmed Chronic Idiopathic Constipation